| | Cdk inhibitors (Alias(es)) | Generation | Principal antikinase activity | Clinical trials for the treatment of tumors |
| | Seliciclib (CYC-202;R-roscovitine) | I | Cdk1, 2, 5, 7, 9; CK1; GSK3A; DIRK1A; ERK1 | Phases I-II for nonsmall cell lung cancer (NSCLC) and other solid tumors |
| | Alvocidib (flavopiridol) | I | Cdk1, 2, 4, 6, 7, 9; GSK3β | Phases I-II for various types of cancers, such as multiple myeloma, leukemia, lymphomas, sarcoma, and solid tumors |
| | Dinaciclib (SCH727965) | I | Cdk1, 2, 5, 9 | Phases I-II for various solid tumors; phases I-II for acute myelogenous leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and B cell chronic lymphocytic leukemia |
| | SNS-032 (BMS-387032) | I | Cdk1, 2, 4, 7, 9 | Phases I-II for B-cell malignancies, nonsmall cell lung cancer (NSCLC), advanced breast cancer, and melanoma |
| | AG-024322 | I | Cdk1, 2, 4, 7 | Phase I for non-Hodgkin’s lymphoma and advanced solid tumors |
| | R547 (R0-4584820) | I | Cdk1, 2, 4, 7 | Phase I for advanced solid tumors |
| | P276-00 | II | Cdk1; Cdk4; Cdk9 | Phases I-II for multiple myeloma and various advanced refractory malignancies |
| | PD-0332991 | II | Cdk4, Cdk6 | Phase I for non-Hodgkin’s lymphoma, mantle cell lymphoma, and other malignancies |
| | AT-7519 | II | Cdk2, Cdk4, Cdk5, Cdk9; GSK3β | Phases I-IIa for advanced and/or metastatic solid tumors and refractory non-Hodgkin’s lymphoma |
| | RGB-286638 | II | Cdk1, Cdk2, Cdk4, Cdk5, Cdk7, Cdk9 | Entering a phase I clinical trial for the treatment of advanced solid tumors |
| | ZK 304709 | III | Cdk1, 2, 4, 7, 9; VEGFR1, 2, 3;
PDGFR-b; Flt-3 | Phase I trials for refractory and/or relapsed solid tumors |
| | GPC-286199 (RGB-286199) | III | Cdk1, 2, 3, 5, 7, 9; CRKs | Preclinical stage |
| | JNJ-7706621 | III | Cdk1, 2, 3; Aurora A/B | Preclinical stage |
|
|
